Implication de nouveaux produits biologiques sur la réponse du stress au réticulum endoplasmique chez les cellules myéloïdes humaines – Year Two

Ce projet vise à élucider davantage le mode d’action de certains produits élaborés par ProMetic BioSciences inc. sur certaines cellules myéloïdes humaines en relation avec une réponse cellulaire impliquée dans un nombre grandissant de maladies humaines. Il s’agit d’un stress du réticulum endoplasmique (RE), un organite cellulaire impliqué dans la synthèse des protéines. Cette dernière […]

Read More
Metric Development to Interpret Measures of Medication Compliance

Medication non-compliance is associated with poor outcomes in patients. Although different methods are currently used to measure compliance, the ability to translate this measure into a meaningful metric, which is interpretable for both methodologists and clinicians, has not yet been realized. Medication compliance has become an increasingly important area of research as policy makers perceive […]

Read More
Mathematical Modeling in Pharmaceutical Development

Microtubules are a key constituent of the cell’s structural framework and are responsible for a diverse range of functions within the cell. They are cylindrical polymers, 25 nm in diameter and can grow to be several hundred micrometers in length. Tubulin, the protein which is the main component of microtubules, self-assembles to form the walls […]

Read More
Data Mining in the VISTA Clinical Trials Database

The project aims to apply data mining in the VISTA clinical trails database at the Geriatric Medicine Research Unit. The data contains information about Alzheimer’s disease (AD) patients, some of whom received cholinergic treatment and some of whom did not receive this treatment. Because of the variability of responses to treatment as well as the […]

Read More
Development of a Pharmacokinetic and Physiologic Model of Different Formulations of an Anti-tumoral Agent

In partnership with Labopharm, a leading company in optimizing the performance of small molecule drugs, a complete pharmacokinetic (PK) study of three new formulations of a commercially available drug will be performed. This study will be conducted in order to choose the most appropriate formulation in terms of bioavailability and absorption rate. Pharmacokinetics parameters of […]

Read More
Improving Patient Safety by Developing an Algorithm to Detect Patient Respiratory Status During Remifentanil Administration for Lithotripsy

Remifentanil, an anesthetic that is administered intravenously during acoustic shock wave treatment for kidney stones, depresses a patient's ability to breathe and can lead to apnea. Respiration is normally detected via standard patient monitors which sound alarms in the event that the patient ceases to breathe for a given length of time. However, a physician […]

Read More
Development and Pharmacological Evaluation of Novel Oral Amphotericin B Formulations for the Treatment of Experimental Systemic Fungal Infections: Providing New Therapeutic Approach for an Unmet Medical Need in First and Third World Countries

Amphotericin B is the most effective, and frequently the only treatment available for a number of life-threatening diseases, including systemic fungal infections and visceral leishmaniasis. The drawbacks of today’s amphotericin B treatment are toxicity and the need to administer the drug intravenously in hospital settings. The need for intravenous administration is due to poor absorption […]

Read More
Cost Shifting of Pharmaceuticals from Public to Private Healthcare Payers

Pharmaceuticals are among the most commonly used and important healthcare treatments in Canada. They are also the second largest single healthcare expenditure and are the fastest increasing healthcare expenditure. For employers, pharmaceuticals are the largest component of their health benefits package and employees cite drugs as being the most valuable part of their employer-funded health […]

Read More
Developing highly sensitive biosensors for MRSA bacterial detection

Nosocomial infection is a growing problem in Canadian hospitals, these bacteria can kill as many as 8,000 patients per year, and the expenses reach at least $100 million annually. Clostridium difficile (C. difficile) and methicillin‐resistant Staphylococcus aureus (MRSA) are among the most common bacteria. For example, C. difficile has killed more than 600 people in […]

Read More
Identification of Protein Targets for a Proprietary Antibody Generation Technology

Amorfix Life Sciences has had success producing highly specific antibodies, which can be used to diagnose disease. The company has recently gained access to an algorithm (ProMISTM) which allows to predict antibody targets on proteins in their diseased state, allowing development of very specific antibodies with diagnostic and therapeutic potential. The proposed project involves a […]

Read More
Rescue of Endoplasmic Reticulum Associated Degradation of F508CFTR Protein in Cystic Fibrosis by Stop Transfer Sequence Containing Verotoxin

The intern will generate DNA sequences to make modified verotoxin proteins that will effectively disrupt the breakdown of a mutant protein (the CFTR protein) that is found in patients with cystic fibrosis. The mutant CFTR protein has normal function but is degraded in cystic fibrosis individuals because of the mutation. The modified verotoxin will reduce […]

Read More